Medical Developments Financials

MVP Stock   0.68  0.08  10.53%   
We recommend to make use of Medical Developments International analysis to find out if markets are presently mispricing the entity. We were able to interpolate data for twenty-seven available fundamentals for Medical Developments, which can be compared to its peers in the industry. The stock experiences a very speculative upward sentiment. Check odds of Medical Developments to be traded at 0.646 in 90 days. Key indicators impacting Medical Developments' financial strength include:
Operating Margin
0.0551
Profit Margin
(0.78)
EPS Estimate Current Year
(0)
Return On Equity
(0.45)
  
Please note, the imprecision that can be found in Medical Developments' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medical Developments International. Check Medical Developments' Beneish M Score to see the likelihood of Medical Developments' management manipulating its earnings.

Medical Developments Stock Summary

Medical Developments competes with Home Consortium, Ambertech, EROAD, WiseTech Global, and Thorney Technologies. Medical Developments is entity of Australia. It is traded as Stock on AU exchange.
Foreign Associates
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentAustralia Stock View All
ExchangeAustralian Securities Exchange
ISINAU000000MVP2
Business Address4 Caribbean Drive,
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitemedicaldev.com
Phone61 3 9547 1888
You should never invest in Medical Developments without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Medical Stock, because this is throwing your money away. Analyzing the key information contained in Medical Developments' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Medical Developments Key Financial Ratios

Medical Developments' financial ratios allow both analysts and investors to convert raw data from Medical Developments' financial statements into concise, actionable information that can be used to evaluate the performance of Medical Developments over time and compare it to other companies across industries.

Medical Developments Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets100.2M101.4M109.5M59.2M68.0M44.3M
Net Debt(33.2M)(17.6M)(22.1M)(7.4M)(6.7M)(7.0M)
Accounts Payable3.3M9.4M13.3M8.3M9.5M10.0M
Cash36.3M20.4M24.7M9.7M11.2M7.9M
Net Receivables5.0M6.2M8.9M7.1M8.1M8.5M
Inventory5.7M7.1M8.4M8.8M10.1M10.6M
Other Current Assets397K620K791K565K649.8K482.7K
Total Liab31.9M44.1M28.2M13.4M15.4M16.1M
Total Current Assets47.4M34.4M42.8M26.1M30.1M15.1M
Short Term Debt337K348K352K371K333.9K494.4K
Intangible Assets8.2M8.0M8.5M3.0M3.5M4.3M
Common Stock41.0M76.9M77.0M105.7M121.6M127.7M
Other Current Liab3.3M683K1.6M639K734.9K698.1K
Other Liab30.3M22.2M22.0M2.2M2.6M2.4M
Retained Earnings(12.1M)(24.5M)(30.2M)(62.9M)(56.6M)(53.7M)
Other Assets35.1M40.7M8.1M4.6M5.3M5.0M
Net Tangible Assets32.3M62.3M51.7M75.7M87.1M91.4M
Long Term Debt Total2.9M2.7M2.5M2.2M2.5M2.6M
Net Invested Capital68.3M57.3M81.3M45.7M52.6M54.1M

Medical Developments Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense121K103K95K86K98.9K78.2K
Total Revenue25.3M21.9M32.3M33.1M38.1M40.0M
Gross Profit16.7M(3.1M)(2.5M)24.4M28.0M29.4M
Operating Income(5.2M)(15.7M)(20.3M)(16.9M)(15.2M)(14.4M)
Ebit(14.9M)(15.8M)(7.4M)(32.8M)(29.6M)(28.1M)
Ebitda(11.1M)(12.9M)(4.3M)(29.4M)(26.5M)(25.2M)
Income Before Tax(15.0M)(15.9M)(7.5M)(32.9M)(29.6M)(28.2M)
Income Tax Expense(2.4M)(3.5M)(1.9M)8.1M7.3M7.6M
Cost Of Revenue8.6M25.0M34.9M8.8M10.1M7.4M
Net Income(12.6M)(12.4M)(5.6M)(41.0M)(36.9M)(35.0M)
Research Development396K536K220K236K271.4K195.6K
Tax Provision(2.4M)(3.5M)(1.9M)8.1M9.3M9.7M
Net Interest Income(50K)(58K)562K316K363.4K381.6K
Interest Income71K45K657K402K462.3K243.6K

Medical Developments Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash20.7M(15.9M)4.3M(14.9M)(13.4M)(12.8M)
Free Cash Flow(15.4M)(15.9M)(24.2M)(13.9M)(12.6M)(11.9M)
Depreciation3.7M2.9M3.1M3.4M3.9M4.1M
Other Non Cash Items8.9M9.8M(5.4M)22.6M26.0M27.3M
Capital Expenditures6.6M5.2M7.7M3.2M3.6M2.5M
Net Income(12.6M)(12.4M)(5.6M)(41.0M)(36.9M)(35.0M)
End Period Cash Flow36.3M20.4M24.7M9.7M11.2M8.2M
Dividends Paid2.1M35.5M139K26.4M30.3M31.9M
Change To Inventory154K(1.4M)(1.8M)(393K)(353.7K)(371.4K)
Net Borrowings(288K)(232K)(215K)(253K)(227.7K)(239.1K)
Change To Netincome(2.6M)7.5M1.7M(12.1M)(10.9M)(10.3M)
Investments(6.5M)(5.2M)(7.1M)(3.2M)(3.6M)(3.8M)

Medical Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Medical Developments's current stock value. Our valuation model uses many indicators to compare Medical Developments value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medical Developments competition to find correlations between indicators driving Medical Developments's intrinsic value. More Info.
Medical Developments International is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medical Developments' earnings, one of the primary drivers of an investment's value.

Medical Developments Systematic Risk

Medical Developments' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Medical Developments volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Medical Developments correlated with the market. If Beta is less than 0 Medical Developments generally moves in the opposite direction as compared to the market. If Medical Developments Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Medical Developments is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Medical Developments is generally in the same direction as the market. If Beta > 1 Medical Developments moves generally in the same direction as, but more than the movement of the benchmark.

Medical Developments International Total Assets Over Time

Medical Developments Thematic Clasifications

Medical Developments International is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
DrugsView
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas

Medical Developments February 27, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Medical Developments help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Medical Developments International. We use our internally-developed statistical techniques to arrive at the intrinsic value of Medical Developments International based on widely used predictive technical indicators. In general, we focus on analyzing Medical Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Medical Developments's daily price indicators and compare them against related drivers.

Additional Tools for Medical Stock Analysis

When running Medical Developments' price analysis, check to measure Medical Developments' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medical Developments is operating at the current time. Most of Medical Developments' value examination focuses on studying past and present price action to predict the probability of Medical Developments' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medical Developments' price. Additionally, you may evaluate how the addition of Medical Developments to your portfolios can decrease your overall portfolio volatility.